Nancy Christmas, MD
Retina Specialist · Denver, CONPI 1619927456
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $10,286 of the $12,323 with a category attached, or 83.5%. US Retina LLC accounts for 83.5% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $3,920 and has fallen 96.6% since, to $133 in 2025.
Across 69 payments — averaging $178.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$10K
- AbbVie$971
- Regeneron Healthcare Solutions, Inc.$312
- Astellas Pharma US Inc$148
- Novartis$95
- Biogen$84
- plus $427 from 8 others
Across 209 payments — averaging $3651.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Apellis Pharmaceuticals, Inc.$763K
What the payments were for
- Grants$831%
- Food & beverage$1,20310%
- Education$7506%
- Ownership interest$10,28683%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 4 | $10,286 |
| AbbVie(2 entities) | 16 | $971 |
| Regeneron Healthcare Solutions, Inc. | 13 | $312 |
| Astellas Pharma US Inc | 8 | $148 |
| Novartis | 6 | $95 |
| Biogen | 5 | $84 |
| Genentech USA, Inc. | 5 | $76 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $75 |
| Bausch & Lomb Americas Inc. | 3 | $63 |
| Apellis Pharmaceuticals, Inc. | 2 | $61 |
| Coherus Oncology, Inc. | 2 | $51 |
| Alimera Sciences, Inc. | 2 | $48 |
| Mallinckrodt Hospital Products Inc. | 1 | $35 |
| Harrow Eye, LLC | 1 | $18 |
How this compares
$12,323 in reported general payments places this provider in the 75th percentile of 51 retina specialist providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 58 | $2,354 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 21 | $275 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Denver
- Alan KimuraDenver$546K
- Brian JoondephDenver$92K
- Jesse SmithDenver$7K
- Miriah TeeterDenver$3K
- Diana ReevesDenver$3K
- Mariana HarasawaDenver$332
- Murtaza AdamParker$548K
- Talisa ForestAurora$84K
- Sara HaugDurango$59K
- Matthew ManryLongmont$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.